Wake Forest Baptist Health Trials

Wake Forest Baptist Health	Welcome, Profile Billing Logout

Wake Forest Baptist Health

Welcome, Profile Billing Logout

28 Trials

10 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Miller, Scott

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting

1/2

192

Canada, US

Peanut SLIT-tablet, Placebo

ALK-Abelló A/S, Parexel

Peanut Allergy

01/26

02/26

BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting

1/2

300

US, RoW

CAB-AXL-ADC, PD-1 inhibitor

BioAtla, Inc.

Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

01/25

Craft, Suzanne

START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting

540

CT1812, Study Drug Active, Placebo, Matching Placebo

Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium

Early Alzheimer's Disease

04/27

Ard, Jamy D

LEAP, NCT05176626: Long-term Effectiveness of the Antiobesity Medication Phentermine

Active, not recruiting

870

Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG, Lomaira

Wake Forest University Health Sciences, Johns Hopkins University, Kaiser Permanente, HealthPartners Institute, The University of Texas Health Science Center, Houston, Biomedical Research Institute of New Mexico, WW International Inc, KVK-Tech, Inc., National Heart, Lung, and Blood Institute (NHLBI)

Obesity, Obesity; Drug, Lifestyle, Healthy

12/26

ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting

1576

Japan, US, RoW

Orforglipron, LY3502970, Semaglutide

Eli Lilly and Company

Type 2 Diabetes

09/25

NCT04994769: The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

Completed

N/A

Epitomee Capsule, The MODEL IBT Program

Epitomee medical

Overweight and Obesity

12/23

03/24

NCT04663061: Diabetes Data-Assisted Remission Trial (DDART)

Completed

N/A

Medical weight loss, Diabetes education, Continuous glucose monitoring

Wake Forest University Health Sciences, UnitedHealth Group

Type 2 Diabetes, Obesity

11/24

VITAL-CGM, NCT05935514: Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

Active, not recruiting

N/A

152

WW Intervention, Usual Care

Pennington Biomedical Research Center, WW International Inc

Diabetes Mellitus, Type 2 Diabetes, Obesity

11/25

Mintz, Akiva

NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting

Europe, US

[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy

Novartis Pharmaceuticals

Glioblastoma

03/27

04/28

Parker-Autry, Candace Y

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Miller, Scott

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting

1/2

192

Canada, US

Peanut SLIT-tablet, Placebo

ALK-Abelló A/S, Parexel

Peanut Allergy

01/26

02/26

BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting

1/2

300

US, RoW

CAB-AXL-ADC, PD-1 inhibitor

BioAtla, Inc.

Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

01/25

Craft, Suzanne

START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting

540

CT1812, Study Drug Active, Placebo, Matching Placebo

Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium

Early Alzheimer's Disease

04/27

Ard, Jamy D

LEAP, NCT05176626: Long-term Effectiveness of the Antiobesity Medication Phentermine

Active, not recruiting

870

Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG, Lomaira

Obesity, Obesity; Drug, Lifestyle, Healthy

12/26

ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting

1576

Japan, US, RoW

Orforglipron, LY3502970, Semaglutide

Eli Lilly and Company

Type 2 Diabetes

09/25

NCT04994769: The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

Completed

N/A

Epitomee Capsule, The MODEL IBT Program

Epitomee medical

Overweight and Obesity

12/23

03/24

NCT04663061: Diabetes Data-Assisted Remission Trial (DDART)

Completed

N/A

Medical weight loss, Diabetes education, Continuous glucose monitoring

Wake Forest University Health Sciences, UnitedHealth Group

Type 2 Diabetes, Obesity

11/24

VITAL-CGM, NCT05935514: Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

Active, not recruiting

N/A

152

WW Intervention, Usual Care

Pennington Biomedical Research Center, WW International Inc

Diabetes Mellitus, Type 2 Diabetes, Obesity

11/25

Mintz, Akiva

NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting

Europe, US

[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy

Novartis Pharmaceuticals

Glioblastoma

03/27

04/28

Parker-Autry, Candace Y

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites